NASDAQ : INDP
-$0.07 (-2.77%)
NASDAQ
Junyi Dai
Biotechnology
Healthcare
INDP
5
US
USD
0.00
2.34
2.34
1.61
0.00
-$
0.00
4.27
-0.25
-7.97
-$21.58
-$20.85M
0.00%
0.00%
-1028.81%
-864.69%
-0.39
0.00
0.00
2/5
2 Analysts
%
-78.81
3/9
$1.25M
$2.18M
$933K
-$18.86M
$2.8M
0.00
-0.15
2.34
-1028.81%
-1396.04%
-354.41%
-401.82%
0 days
| Name | Title |
|---|---|
| Yu Ding | Chief Financial Officer |
| Junyi Dai | CEO & Chairman |
| Michael J. Newman | Founder, Chief Scientific Officer & Director |
| Walt Addison Linscott | Chief Operating Officer |
No votes yet today — be the first to share your view!
About Indaptus Therapeutics, Inc. (NASDAQ:INDP) Stock
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in Augus ... t of the same year. Its corporate headquarters are situated in New York, New York.
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders
2026-06-17 23:02:00
STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Indaptus Therapeutics, Inc. (Nasdaq: INDP) who held their shares prior to December 22, 2025.
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 07:00:00
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeutics' Chief Executive Officer and Chairman of the Board, commented, “Following recent changes in executive management, the Company has conducted a review of its development programs, operating resources and ongoing corporate initiatives.
Frequently Asked Questions
What is the current Indaptus Therapeutics, Inc. (INDP) stock price?
Indaptus Therapeutics, Inc.(NASDAQ:INDP) stock price is $2.46 in the last trading session. During the trading session, INDP stock reached the peak price of $12.029 while $0.92 was the lowest point it dropped to. The percentage change in INDP stock occurred in the recent session was --2.77% while the dollar amount for the price change in INDP stock was -$0.07.
INDP's industry and sector of operation?
The NASDAQ listed INDP is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of INDP?
Yu Ding
| Chief Financial Officer
Junyi Dai
| CEO & Chairman
Michael J. Newman
| Founder, Chief Scientific Officer & Director
Walt Addison Linscott
| Chief Operating Officer
|
How many employees does INDP have?
Number of INDP employees currently stands at 5. INDP operates from 3 Columbus Circle, New York City, NY 10019, US.
Link for INDP official website?
Official Website of INDP is: https://indaptusrx.com
How do I contact INDP?
INDP could be contacted at phone #347 480 9760 and can also be accessed through its website. INDP operates from 3 Columbus Circle, New York City, NY 10019, US.
How many shares of INDP are traded daily?
The average number of INDP shares traded daily for last 3 months was 1.01M.
What is the market cap of INDP currently?
The market value of INDP currently stands at $4.31M with its latest stock price at $2.46